TYO:2160

4 stories mentioning TYO:2160

Every FINWIRES story that references TYO:2160, newest first.

GNI to Acquire Ayumi Pharmaceutical in 44.8 Billion Yen Deal; Blackstone-Backed Fund Becomes Top Shareholder

GNI (TYO:2160) has resolved to acquire all shares of Ayumi Pharmaceutical for 44.8 billion yen, turning it into a wholly owned subsidiary to gain a commercial platform in Japan's pharmaceutical market, according to three Tokyo bourse filings on Friday.To fund the acquisition, GNI will issue nearly 10 million new shares via third-party allotment to Ayumi's existing shareholders, namely Blackstone affiliate BCP Asia AYM, Toho (TYO:8129), and Hisamitsu Pharmaceutical (TYO:4530), with 26.8 billion yen of the purchase price settled through contribution in kind.The remaining 18 billion yen will be paid in cash, partially financed through a 20 billion yen loan from Mizuho Bank and SBI Shinsei Bank.As a result, BCP Asia AYM will become GNI's largest major shareholder with a 10.63% voting rights stake after the transaction.The deal is expected to close between June and September, pending regulatory approvals and securities registration effectiveness.Ayumi Pharmaceutical owns Ayumi Pharmaceutical Co., a maker of antipyretic analgesics and anti-rheumatic drugs, which has shown steady revenue growth from 31 billion yen to 38.5 billion yen over three years.

TYO:2160TYO:4530TYO:8129

Asia33d ago

Japan Shares Rise on BOJ Rate Hike Expectations

Japanese shares ended higher on Wednesday after the OECD projected the Bank of Japan's (BOJ) policy rate could rise to 2% by the end of 2027, reinforcing expectations of a sustained monetary-tightening cycle.The Nikkei 225 rose 0.8%, or 529.54 points, to close at 63,272.11.The OECD said the Japanese central bank's policy rate remains near the low end of the economy's neutral range and urged gradual rate hikes as inflation stays around 2% and demand continues to outpace supply.OECD Secretary-General Mathias Cormann said the pace of policy normalization could accelerate as Japan's economic equilibrium becomes clearer, though he said the BOJ was not yet "behind the curve."The OECD projected the BOJ's policy rate could reach 2% by end-2027 as the central bank continues unwinding monetary easing toward a neutral rate estimated at 1.1% to 2.5%.In economic news, Japan's current account surplus widened 29.1% year over year to 4.682 trillion yen in March, driven by higher primary income and a wider goods surplus.Japan's bank lending growth accelerated to 5.4% year over year in April, led by solid loan expansion at major banks and continued strength at regional lenders.On the corporate front, Bandai Namco (TYO:7832) rose 5% after reporting stronger fiscal 2026 profit and sales growth, driven by robust demand for its Gundam franchise and Toys and Hobby business.Tsugami (TYO:6101) climbed 7% after its China segment profit jumped 39% year over year on stronger revenue growth. Meanwhile, GNI Group (TYO:2160) advanced 9% after its liver fibrosis drug F351 was accepted for regulatory review in China with priority review status.

Nikkei 225TYO:2160TYO:6101TYO:7832

Asia33d ago

GNI Group's NDA Application for Liver Fibrosis Drug Accepted for Review in China

GNI Group (TYO:2160) said its investigational drug F351 has been accepted for regulatory review in China, marking a key step toward potential approval for treating liver fibrosis linked to chronic hepatitis B, according to a Wednesday filing on the Tokyo Stock Exchange.The application, submitted through its China-based subsidiary Gyre Therapeutics, has moved into substantive evaluation by China's drug regulator following validation of the filing.F351, also known as hydronidone, has been granted priority review status by China's National Medical Products Administration, a designation that can shorten assessment timelines for therapies with significant clinical value.The treatment targets liver fibrosis caused by chronic hepatitis B, a major health burden in Asia that can progress to cirrhosis and liver cancer if untreated, with limited existing therapeutic options.

TYO:2160

Asia56d ago

GNI Group Subsidiary Starts Phase 2/3 Trial of Pirfenidone

GNI Group (TYO:2160) said its unit Gyre Pharmaceuticals enrolled the first patient in a Phase 2/3 trial of pirfenidone for radiation-induced lung injury, according to a Monday filing on the Tokyo Stock Exchange.The study will assess the drug's safety and efficacy in treating lung damage linked to cancer radiotherapy, including cases involving immune-related pneumonitis.Pirfenidone, marketed as Etuary, is already approved for idiopathic pulmonary fibrosis and is being expanded into oncology supportive care.

TYO:2160